

### Biovica to present at Stora Aktiedagen focused on Life Science, held in Lund the 29<sup>th</sup> of January 2019

**Uppsala, January 23, 2019. Biovica will present at Stora Aktiedagen focused on Life Science, a small-cap investor conference, held on January 29, 2019 at Medicon Village, Scheelevägen 2 in Lund. The event is arranged by Aktiespararna and the company will be represented by CEO Anders Rylander 12.50 CET.**

For full program and registration, see link <https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-29-januari-0>

The event will be webcasted on [www.aktiespararna.se/tv/live](http://www.aktiespararna.se/tv/live) and on demand at [www.aktiespararna.se/tv/evenemang](http://www.aktiespararna.se/tv/evenemang).

#### Contact

Anders Rylander, CEO Biovica.

Phone: +46 (0)18 444 48 35,

E-mail: [anders.rylander@biovica.com](mailto:anders.rylander@biovica.com)

In the event of contradictions or differences between the Swedish press release and this English translation of the Swedish press release, the Swedish text shall be given priority.

#### Biovica – Best Possible Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE labelled and MPA registered. Appointed Certified Adviser is FNCA Sweden AB, [info@fnca.se](mailto:info@fnca.se), +46 8 528 00 399.

Webb [www.biovica.com](http://www.biovica.com)

Contact [info@biovica.com](mailto:info@biovica.com)